Classic CRC biomarkers, such as mutations in KRAS and BRAF, methylation modifications of NDRG4, BMP3, and SEPT9, high expression of miR-92a and miR-144, and the presence of F. nucleatum, are utilized in liquid biopsies for early CRC screening [8,9,10,11,12]. The gene discussed is KRAS; the disease is colorectal carcinoma.